Ocular Therapeutix Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$138.4M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Ocular Therapeutix's estimated annual revenue is currently $2M per year.(i)
  • Ocular Therapeutix received $37.5M in venture funding in February 2019.
  • Ocular Therapeutix's estimated revenue per employee is $8,057
  • Ocular Therapeutix's total funding is $138.4M.

Employee Data

  • Ocular Therapeutix has 247 Employees.(i)
  • Ocular Therapeutix grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10023%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$138.4M

Total Funding

247

Number of Employees

$2M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ocular Therapeutix News

2022-04-17 - Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected to Post ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected to Post Quarterly Sales of $15.03 Million. Posted by admin on Apr 19th, 2022.

2022-04-13 - Ocular Therapeutix™ to Present Clinical Data at the 2022 ...

Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

2022-03-30 - Ocular Therapeutix: A Follow-Up

This article is an update to my earlier piece in which I explained why I was buying the dip on Ocular Therapeutix (NASDAQ:OCUL),...

2021-07-23 - OCULAR THERAPEUTIX : ANNOUNCES SECOND QUARTER 2021 PRELIMINARY NET PRODUCT REVENUE OF $11.7 MILLION

BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, reported preliminary net product revenue for the quarter ended June 30, 2021, and in ...

2021-07-22 - Ocular Therapeutix : trade; Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary net product revenue for the quarter ended June 30, 2021, and in-market uni ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$39.9M25043%N/A
#2
$91.5M252-39%N/A
#3
$33.5M2540%N/A
#4
$58M2571%N/A
#5
$42.1M26418%N/A

Ocular Therapeutix Funding

DateAmountRoundLead InvestorsReference
2013-01-29$23.8MDMultipleArticle
2013-06-11$UndisclosedUndisclosedBaxter VenturesArticle
2015-06-04$UndisclosedUndisclosedMorgan StanleyArticle
2017-01-25$25.0MUndisclosedCantor Fitzgerald & CoArticle
2018-01-26$37.3MUndisclosedPiper Jaffray & CoArticle
2019-01-02$25.0MUndisclosedMidCap FinancialArticle
2019-02-22$37.5MUndisclosedArticle